ENTRY       D09979                      Drug
NAME        Tralokinumab (USAN/INN);
            Tralokinumab (genetical recombination) (JAN);
            Tralokinumab-ldrm;
            Adbry (TN);
            Adtralza (TN)
PRODUCT     ADBRY (LEO Pharma)
FORMULA     C6374H9822N1698O2014S44
EXACT_MASS  143784.6063
MOL_WEIGHT  143873.2167
SEQUENCE    (Heavy chain)
            QVQLVQSGAE VKKPGASVKV SCKASGYTFT NYGLSWVRQA PGQGLEWMGW ISANNGDTNY
            GQEFQGRVTM TTDTSTSTAY MELRSLRSDD TAVYYCARDS SSSWARWFFD LWGRGTLVTV
            SSASTKGPSV FPLAPCSRST SESTAALGCL VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ
            SSGLYSLSSV VTVPSSSLGT KTYTCNVDHK PSNTKVDKRV ESKYGPPCPS CPAPEFLGGP
            SVFLFPPKPK DTLMISRTPE VTCVVVDVSQ EDPEVQFNWY VDGVEVHNAK TKPREEQFNS
            TYRVVSVLTV LHQDWLNGKE YKCKVSNKGL PSSIEKTISK AKGQPREPQV YTLPPSQEEM
            TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS RLTVDKSRWQ
            EGNVFSCSVM HEALHNHYTQ KSLSLSLGK
            (Light chain)
            SYVLTQPPSV SVAPGKTARI TCGGNIIGSK LVHWYQQKPG QAPVLVIYDD GDRPSGIPER
            FSGSNSGNTA TLTISRVEAG DEADYYCQVW DTGSDPVVFG GGTKLTVLGQ PKAAPSVTLF
            PPSSEELQAN KATLVCLISD FYPGAVTVAW KADSSPVKAG VETTTPSKQS NNKYAASSYL
            SLTPEQWKSH RSYSCQVTHE GSTVEKTVAP TECS
            (Disulfide bridge: H22-H96, H149-H205, H263-H323, H369-H427, H228-H'228, H231-H'231, L22-L87, L136-L195, H136-L213)
  TYPE      Peptide
CLASS       Immunological agent
             DG02019  Interleukin inhibitor
REMARK      Therapeutic category: 4490
            ATC code: D11AH07
            Product: D09979<JP/US>
EFFICACY    Antiasthmatic, Anti-inflammatory, Anti-IL-13 antibody
  DISEASE   Atopic dermatitis [DS:H01358]
  TYPE      Monoclonal antibody
COMMENT     Treatment of asthma and inflammatory diseases
TARGET      IL13 [HSA:3596] [KO:K05435]
  PATHWAY   hsa04060(3596)  Cytokine-cytokine receptor interaction
            hsa04630(3596)  JAK-STAT signaling pathway
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             D DERMATOLOGICALS
              D11 OTHER DERMATOLOGICAL PREPARATIONS
               D11A OTHER DERMATOLOGICAL PREPARATIONS
                D11AH Agents for dermatitis, excluding corticosteroids
                 D11AH07 Tralokinumab
                  D09979  Tralokinumab (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Dermatological Agents
              Dermatitis and Pruitus Agents
               Dermatitis and Pruitus Agents, Other
                Tralokinumab
                 D09979  Tralokinumab (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              44  Allergic agents
               449  Miscellaneous
                4490  Miscellaneous
                 D09979  Tralokinumab (USAN/INN); Tralokinumab (genetical recombination) (JAN)
            Drug groups [BR:br08330]
             Immunological agent
              DG02019  Interleukin inhibitor
               D09979  Tralokinumab
            Drug classes [BR:br08332]
             Immunological agent
              DG02019  Interleukin inhibitor
               D09979  Tralokinumab
            Target-based classification of drugs [BR:br08310]
             Cytokines and receptors
              Cytokines
               Interleukins
                IL13
                 D09979  Tralokinumab (USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D09979
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D09979
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D09979
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D09979
DBLINKS     CAS: 1044515-88-9
            PubChem: 135626700
///
